Wellington Management led a $90m Seriec C round in Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies, with participation from Cormorant Asset Management, Monashee Investment Management, Highside Capital Management, Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital and Renaissance Venture Capital Fund. "We are grateful to our new and existing investors for their commitment to our bold mission of delivering the best possible treatment for each patient, as early as possible. This financing will enable us to increase our investment in our platform, programs, and team, as we combine highly sensitive MRD testing with DNA and quantitative RNA-informed treatment selection testing," Dan Rhodes, Strata Oncology CEO.